New "triptans" and other drugs for migraine.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000639:Amitriptyline / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D004087:Dihydroergotamine / Q000627:therapeutic use; D004347:Drug Interactions; D004878:Ergotamine / Q000627:therapeutic use; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D008784:Methysergide / Q000627:therapeutic use; D008881:Migraine Disorders / Q000188:drug therapy* / Q000517:prevention & control; D009288:Naproxen / Q000627:therapeutic use; D010080:Oxazoles / Q000627:therapeutic use; D023303:Oxazolidinones; D010880:Piperidines / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use; D017366:Serotonin Receptor Agonists / Q000494:pharmacology / Q000627:therapeutic use*; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology; D018170:Sumatriptan / Q000627:therapeutic use; D013997:Time Factors; D013999:Timolol / Q000627:therapeutic use; D014230:Triazoles / Q000627:therapeutic use; D014363:Tryptamines; D014635:Valproic Acid / Q000627:therapeutic use; D014662:Vasoconstrictor Agents / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000639:Amitriptyline; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000929:Antidepressive Agents, Tricyclic; D002121:Calcium Channel Blockers; D004087:Dihydroergotamine; D004878:Ergotamine; D007211:Indoles; D008784:Methysergide; D009288:Naproxen; D010080:Oxazoles; D023303:Oxazolidinones; D010880:Piperidines; D011433:Propranolol; D017366:Serotonin Receptor Agonists; D017367:Selective Serotonin Reuptake Inhibitors; D018170:Sumatriptan; D013999:Timolol; D014230:Triazoles; D014363:Tryptamines; D014635:Valproic Acid; D014662:Vasoconstrictor Agents; C089750:zolmitriptan; C093622:rizatriptan; C106783:naratriptan